|
C17ORF53 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.5368817329886E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.31999974786845E-11 |
| Normal-vs-Stage2 |
1.149790E-02 |
| Normal-vs-Stage3 |
4.62540006296308E-11 |
| Normal-vs-Stage4 |
2.59819998849053E-09 |
| Stage1-vs-Stage2 |
6.403000E-03 |
| Stage1-vs-Stage3 |
1.500000E-01 |
| Stage1-vs-Stage4 |
8.895400E-03 |
| Stage2-vs-Stage3 |
1.420040E-03 |
| Stage2-vs-Stage4 |
1.620120E-04 |
| Stage3-vs-Stage4 |
2.135400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63413726994577E-12 |
| Normal-vs-AfricanAmerican |
2.020700E-03 |
| Normal-vs-Asian |
3.18750004169033E-09 |
| Caucasian-vs-AfricanAmerican |
3.537600E-01 |
| Caucasian-vs-Asian |
2.547600E-01 |
| AfricanAmerican-vs-Asian |
7.433600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.3422996048007E-10 |
| Normal-vs-Female |
6.0089710984812E-12 |
| Male-vs-Female |
5.249000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.108047235718E-12 |
| Normal-vs-Age(41-60Yrs) |
1.94310001422338E-09 |
| Normal-vs-Age(61-80Yrs) |
2.3995999964832E-08 |
| Normal-vs-Age(81-100Yrs) |
1.750190E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.609900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.802000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.926800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.272600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.764960E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.466050E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.241500E-03 |
| Classical-VS-Follicular |
2.22044604925031E-16 |
| Classical-VS-Other |
1.528800E-01 |
| Classical-VS-Normal |
2.1094237467878E-15 |
| Tall-VS-Follicular |
5.32907051820075E-15 |
| Tall-VS-Other |
1.038350E-03 |
| Tall-VS-Normal |
1.6269208202857E-12 |
| Follicular-VS-Other |
2.429200E-01 |
| Follicular-VS-Normal |
1.663970E-01 |
| Other-VS-Normal |
6.338300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.40010003380331E-09 |
| Normal-vs-N1 |
2.26999996577604E-09 |
| N0-vs-N1 |
1.302180E-02 |
|
|
